Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Inhaled immunotherapy shows promise for canine lung cancer
The study used interleukin-15 to reinvigorate the immune system.

Research could also have benefits for humans with the disease. 

US researchers have discovered that a protein naturally produced by the body could become a vital new immunotherapy drug in the fight against cancer.

Scientists at UC Davis and other institutions conducted a trial on 21 dogs with metastatic lung disease from osteosarcoma and melanoma. For 14 days, the dogs inhaled a mist containing interleukin-15 (IL-15) - a protein previously recognised for its immunotherapy properties.

The results, published in the Journal for ImmunoTherapy of Cancer, show that amplified concentrations of IL-15 can stimulate immune system defenses against some types of cancers in dogs. 

“No one previously had administered IL-15 as an inhaled treatment in dogs to deliver it directly to the site of the cancer,” explained Dr Rober Canter, a surgical oncologist at UC Davis Comprehensive Cancer Center. “We came up with that idea as a means of reducing exposure to the rest of the body, in order to improve the benefit-risk ratio, to improve the immune stimulating effects, and to reduce toxicity.”

“In this study, we used interleukin-15 to reinvigorate the immune system to make it recognize the cancer cells that had evaded the immune system and eliminate them.”

In the first-of-its-kind trial, the dogs began to show significant responses to the protein two weeks after they begain inhaling the mist. 

In two dogs, tumours shrank dramatically – including one that went into complete remission for more than a year. Furthermore, cancer that had been growing rapidly in five other dogs stabilised for several months - with the overall response rate being close to 40 per cent.

While more research is yet to be carried out, the team hopes that its findings will also benefit humans with advanced metastatic cancer.

“As part of our comparative oncology research, we are strong advocates of clinical trials in companion dogs, especially for immunotherapy, as a way to speed bench-to-bedside translation,” added Dr Canter. “The cancers that afflict dogs, including sarcomas, brain tumors, lymphoma and melanoma, are incredibly similar to cancers that humans develop.” 

Become a member or log in to add this story to your CPD history

RCVS Knowledge appoints Veterinary Evidence editor-in-chief

News Story 1
 RCVS Knowledge has welcomed Professor Peter Cockcroft as editor-in-chief for Veterinary Evidence.

A world-renowned expert in evidence-based veterinary medicine, Prof Cockcroft will lead the strategic development and editorial quality of the open-access journal. He was previously in the role from 2017-2020.

Katie Mantell, CEO of RCVS Knowledge, said: "We are excited about the extensive knowledge of evidence-based veterinary medicine and clinical veterinary research that Peter brings, and we look forward to working with him over this next phase of the journal's development." 

Click here for more...
News Shorts
Defra to host bluetongue webinar for vets

The Department for Environment, Food and Rural Affairs (Defra) will be hosting a webinar for veterinary professional on bluetongue on Thursday, 25 April 2024.

Topics covered will include the transmission cycle, pathology and pathogenesis, clinical signs (including signs seen in recent BTV-3 cases in the Netherlands), and control and prevention.

The session, which will take place from 6pm to 7.30pm, is part of Defra's 'Plan, Prevent and Protect' webinar series, which are hosted by policy officials, epidemiologists and veterinary professionals from Defra and the Animal and Plant Health Agency. The bluetongue session will also feature insights from experts from The Pirbright Institute.

Those attending will have the opportunity to ask questions. Places on the webinar can be booked online.